Dual Blockade of HER2 - Twice as Good or Twice as Toxic?

Clinical Oncology

Volumn 24, Issue 9, 2012, Pages 593-603

  Fralick, M ^a   Hilton, J F ^b   Bouganim, N ^b   Clemons, M ^b   Amir, E ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b OTTAWA REGIONAL CANCER CENTRE   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

Breast cancer; HER2 neu; Lapatinib; Neratinib; Pertuzumab; Trastuzumab

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; FLUOROURACIL; LAPATINIB; LIVER ENZYME; NERATINIB; PACLITAXEL; PERTUZUMAB; TRASTUZUMAB;

ADJUVANT THERAPY; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURGERY; COMPARATIVE STUDY; CONSTIPATION; COUGHING; DERMATITIS; DIARRHEA; DISEASE CONTROL; DRUG HYPERSENSITIVITY; DYSPNEA; FATIGUE; FEBRILE NEUTROPENIA; GRANULOCYTOPENIA; HEADACHE; HUMAN; HYPERSENSITIVITY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; LEUKOPENIA; LIVER DISEASE; MENSTRUAL IRREGULARITY; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PARTIAL MASTECTOMY; PERIPHERAL EDEMA; PERIPHERAL NEUROPATHY; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RECURRENCE FREE SURVIVAL; SIDE EFFECT; SKIN DISEASE; TREATMENT DURATION; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; QUINOLINES; RECEPTOR, ERBB-2;

EID: 84866851239     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2012.05.009     Document Type: Article

References (32)

1. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
2. Slamon D.J., Clark G.M., Wong S.G., et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
3. Yarden Y., Sliwkowski M.X. Untangling the ErbB signaling network. Nat Rev Mol Cell Biol 2001, 2:127-137.
4. Robert N., Leyland-Jones B., Asmar L., et al. Randomized phase III study of trastuzumab, paclitaxel and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006, 24:2786-2792.
5. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
6. Garrett J.T., Arteaga C.L. Resistance to HER2-directed antibodies and tyrosine kinase inhibitors: mechanisms and clinical implications. Cancer Biol Ther 2011, 11:793-800.
7. Nagata Y., Lan K.H., Zhou X., et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 2004, 6:117-127.
8. Zhang S., Huang W.C., Li P., et al. Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways. Nat Med 2011, 17:461-469.
9. Baselga J., Swain S.M. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009, 9:463-475.
10. Campone M., Juin P., Andre F., et al. Resistance to HER2 inhibitors: is addition better than substitution? Rationale for the hypothetical concept of drug sedimentation. Crit Rev Oncol/Hematol 2011, 78:195-205.
11. Montemurro F., Valabrega G., Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Expert Opin Biol Ther 2007, 7:257-268.
12. Ocana A., Amir E. Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: current status and future directions. Cancer Treat Rev 2009, 35:685-691.
13. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010, 28:1124-1130.
14. Gomez H.L., Doval D.C., Chavez M.A., et al. Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 2008, 26:2999-3005.
15. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
16. Anido J., Scaltriti M., Bech Serra J.J., et al. Biosynthesis of tumorigenic HER2 C-terminal fragments by alternative initiation of translation. EMBO J 2006, 25:3234-3244.
17. Storniolo A.M., Pegram M.D., Overmoyer B., et al. Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2008, 26:3317-3323.
18. Blackwell K., Burstein H., Sledge G., et al. Updated survival analysis of a randomized study of lapatinib alone or in combination with trastuzumab in women with HER2-positive metastatic breast cancer progressing on trastuzumab therapy. J Clin Oncol 2009, 69(24):61.
19. Adjuvant lapatinib and/or trastuzumab treatment optimization trial. Available at: http://alttotrials.com/patients.php.
20. Baselga J., Bradbury I., Eidtmann H., et al. First results of the Neo-ALTTO trial (BIG 01-06/EGF 106903): a phase III, randomized, open label, neoadjuvant study of lapatinib, trastuzumab, and their combination plus paclitaxel in women with HER2-positive primary breast cancer 10 December 2010, SABCS, San Antonio, Texas.
21. Guarneri V., Frassoldati A., Bottini A., et al. Final results of a phase II randomized trial of neoadjuvant anthracycline-taxane chemotherapy plus lapatinib, trastuzumab, or both in HER2-positive breast cancer (CHER-LOB trial). ASCO. June 2011. Chicago, Illinois. J Clin Oncol 2011, 29S:507.
22. Holmes F., Nagarwala Y., Espina V., et al. Correlation of molecular effects and pathologic complete response to preoperative lapatinib and trastuzumab, separately and combined prior to neoadjuvant breast cancer chemotherapy. ASCO. June 2011. Chicago, Illinois. J Clin Oncol 2011, 29S:506.
23. Adams C.W., Allison D.E., Flagella K., et al. Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab. Cancer Immunol Immunother 2006, 55:717-727.
24. Baselga J., Gelmon K.A., Verma S., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 2010, 28:1138-1144.
25. Baselga J., Cortes J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012, 366:109-119.
26. Gianni L., Llado A., Bianchi G., et al. Open-label, phase II, multicenter, randomized study of the efficacy and safety of two dose levels of pertuzumab, a human epidermal growth factor receptor 2 dimerization inhibitor, in patients with human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 2010, 28:1131-1137.
27. Rabindran S.K., Discafani C.M., Rosfjord E.C., et al. Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 2004, 64:3958-3965.
28. Gianni L., Pienkowski T., Im Y.H., et al. Neoadjuvant pertuzumab (P) and trastuzumab (H): antitumor and safety analysis of a randomized phase II study ('NeoSphere') 10 December 2010, SABCS, San Antonio, Texas, S3-2.
29. Bose P., Ozer H. Neratinib: an oral, irreversible dual EGFR/HER2 inhibitor for breast and non-small cell lung cancer. Expert Opin Investig Drugs 2009, 18:1735-1751.
30. Burstein H.J., Sun Y., Dirix L.Y., et al. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 2010, 28:1301-1307.
31. Swaby R., Blackwell K., Jiang Z., et al. Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: a phase I/II study. ASCO. June 2009. Orlando, Florida. J Clin Oncol 2009, 27(15S):1004.
32. Miller K., Gianni L., Andre F., et al. A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (TP). J Clin Oncol 2010, 28(suppl 15):1012.